One drop of blood: how Elizabeth Holmes misled Theranos investors, and what KYB would have checked

Theranos promised a full range of blood tests from a finger prick. Its board was one of the most distinguished in American business, its investors put in hundreds of millions of dollars, and Walgreens opened testing centers in its stores. The device at the center of it could run only a few tests. This page tells the story from the court and SEC record, then sets out the checks a KYB or due diligence analyst would run on a company like Theranos.

What really happened

The company and the claim

Elizabeth Holmes founded Theranos in 2003 and served as its chair and CEO; the New York Times described her as a Stanford dropout who held majority control. The Justice Department says she claimed for more than a decade that Theranos had built a revolutionary blood analyzer, variously called the Theranos Sample Processing Unit, Edison and minilab, that could run any test a conventional lab could, from a fingerstick sample, faster, cheaper and more accurately.

Investors in 2014 bought stakes at a price that implied a $9 billion valuation, Forbes reported. Fortune described the board in 2014 as possibly the most illustrious in U.S. corporate history: it included former Secretaries of State George Shultz and Henry Kissinger, former Defense Secretary Bill Perry, former Senators Sam Nunn and Bill Frist, and retired General James Mattis.

What the analyzer could actually do

The SEC charged in March 2018 that Theranos, Holmes and former president Ramesh "Sunny" Balwani raised more than $700 million through an elaborate, years-long fraud. According to the SEC, the proprietary analyzer could complete only a small number of tests, and the company ran the vast majority of patient tests on modified and industry-standard commercial analyzers made by others. The SEC also said Theranos claimed its products were deployed by the Department of Defense in Afghanistan and would bring in more than $100 million in 2014 revenue. In fact the technology was never deployed by the military, and 2014 revenue from operations was a little over $100,000. Holmes settled without admitting or denying the allegations, gave up voting control and accepted a 10-year bar from serving as an officer or director of a public company.

The trial evidence summarized by prosecutors adds more. Holmes showed investors reports bearing pharmaceutical company logos, falsely suggesting those companies had validated the technology. She told investors the Walgreens partnership would grow from a few dozen Wellness Centers to 900 while knowing it was stagnating. In 2010 she projected 2011 revenue of $223 million to one investor; actual revenue fell from $2.8 million in 2009 to under $600,000 in 2011.

Exposure and collapse

In October 2015 the Wall Street Journal published John Carreyrou's investigation into Theranos's technology. The New York Times reported that Theranos then acknowledged running only a limited number of tests on its finger-prick technology, and that Walgreens paused new centers. In June 2016 Walgreens ended the relationship and closed all 40 Theranos Wellness Centers in its Arizona stores.

The verdict and sentence

On January 3, 2022, a jury convicted Holmes of one count of conspiracy to commit wire fraud against investors and three counts of wire fraud on individual investors, involving wire transfers of more than $140 million. She was acquitted on four counts related to patients and one related to patient advertising; the jury deadlocked on three counts. On November 18, 2022, Judge Edward J. Davila sentenced her to 135 months. The Guardian reported that she began her sentence in May 2023 and was ordered to pay $452 million in restitution.

Where the film differs from the record

• "Professors told her it could not work": we did not find this in a source we could fetch, so the page does not rely on it.
• "A reporter found out where the tests really ran": the Journal's 2015 reporting started the unraveling, but the specific finding that most patient tests ran on other makers' analyzers comes from the SEC's complaint. We could not read the paywalled Journal article.
• "Eleven years" rounds 11 years and 3 months. "Convicted of defrauding investors" is accurate; she was acquitted of the patient counts.
• "This week, a new documentary" refers to a release we did not verify.

The film

One Drop of Blood is a 56-second claymation dramatization posted on September 30, 2026. Characters are clay figures and scenes are staged.

Narration transcript

She raised seven hundred million dollars on one drop of blood.

Her name was Elizabeth Holmes. At nineteen, she dropped out of Stanford to build a machine that ran blood tests from a finger prick.

Professors told her it could not work. She built it anyway, and called it Edison.

Investors lined up. The company was worth nine billion dollars.

Former secretaries of state sat on her board. Walgreens put her tests in its stores.

Then a reporter found out where the tests really ran: on ordinary lab machines, made by other companies.

The Edison couldn't do what she said.

In 2022, she was convicted of defrauding investors. Eleven years in prison.

This week, a new documentary put her back on every screen.

The board was famous. The investors were smart. Nobody opened the box.

Sweat AI checks what's really behind the company.

Open the box. Get Sweat AI.

How KYB would have caught it

Theranos was a private company raising money, not a merchant applying for an account, but the checks are the same ones an analyst runs on any counterparty whose value rests on claims about what it does.

Related terms

• Enhanced due diligence
• Evidence packet
• Control person
• Adverse media screening
• Periodic review and perpetual KYB
• Guide: How to verify a business for KYB

When the claims outrun the evidence

Most companies with ambitious claims are telling the truth, and the job is to show which claims have evidence behind them. Sweat AI is an AI-native BPO for banks and fintechs. Our analysts check onboarding and fraud-queue cases against sources the applicant does not control, nights and weekends included. We prepare the review, the evidence and a recommendation, and your team makes the decision. See a finished file in our sample KYB review, or read about our business investigations.